Skip to main content

Table 4 Activity and efficacy by treatment arm and clinical setting

From: Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

  Whole set Locally advanced Metastatic not pre-treated with anthracyclines Metastatic pre-treated with anthracyclines
  3-weekly
N = 69
Weekly
N = 66
3-weekly
N = 22
Weekly
N = 20
3-weekly
N = 26
Weekly
N = 26
3-weekly
N = 21
Weekly
N = 20
Objective response         
   Complete response, n 7 2 2 1 2 - 3 1
   Partial response, n 20 20 9 9 7 7 4 4
   Stable disease, n 19 16 10 8 8 7 1 1
   Progressive disease, n 5 9 - 1 2 4 3 4
   Not evaluable (non responding), n 18 19 1 1 7 8 10 10
   Response rate, % (95% exact CI) 39.1 (27.6-51.6) 33.3 (22.2-46.0) 50.0 (28.2-71.8) 50.0 (27.2-72.8) 34.6 (17.2-55.7) 26.9 (11.6-47.8) 33.3 (14.6-57.0) 25.0 (8.7-49.1)
Progression free survival         
   Progressed patients, n (%) 42 (60.9) 44 (66.7) 6 (27.3) 6 (30.0) 18 (69.2) 20 (76.9) 18 (85.7) 18 (90.0)
   Median, months (95% CI) 15.2 (11.8-36.6) 13.1 (7.7-22.4) n.r. n.r. 11.9 (10.2-36.6) 10.4 (6.2-22.4) 9.1 (5.9-29.7) 6.2 (4.2-14.4)
   HR weekly vs 3 weekly (95% CI) 1.29 (0.84-1.97) 1.10 (0.35-3.45) 1.29 (0.67-2.47) 1.52 (0.78-2.97)
Overall survival         
   Dead patients, n (%) 27 (39.1) 32 (48.5) 3 (13.6) 2 (10.0) 13 (50.0) 15 (57.7) 11 (52.4) 15 (75.0)
Median, months (95% CI) 42.9 (27.7-na) 33.0 (25.2-na) n.r. n.r. 26.7 (21.2-na) 28.5 (11.4-na) 33.2 (16.3-na) 28.8 (19.8-na)
   HR weekly vs 3 weekly (95% CI) 1.38 (0.82-2.30) 0.78 (0.13-4.69) 1.41 (0.67-2.99) 1.54 (0.70-3.36)
  1. n.r. = not reached